A Phase IA, Dose-Escalating Study of LBH589 Administered Intravenously in Adult Patients With Advanced Solid Tumors.
Latest Information Update: 10 Jun 2014
Price :
$35 *
At a glance
- Drugs Panobinostat (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Novartis
- 19 Mar 2010 Actual patient number (14) added as reported by ClinicalTrials.gov.
- 19 Mar 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 13 Sep 2008 New trial record.